These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25573036)

  • 21. Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity.
    Mizuno D; Kimoto T; Takei T; Fukuta A; Shinahara W; Takahashi E; Yano M; Kido H
    Vaccine; 2011 Jul; 29(33):5368-78. PubMed ID: 21669246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
    Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-mediated immune response to epitopic MAP (multiple antigen peptide) construct of LcrV antigen of Yersinia pestis in murine model.
    Shreewastav RK; Ali R; Uppada JB; Rao DN
    Cell Immunol; 2012; 278(1-2):55-62. PubMed ID: 23121976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications.
    Wang CY; Walfield AM
    Vaccine; 2005 Mar; 23(17-18):2049-56. PubMed ID: 15755569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of adaptive immune response by self-aggregating peptides.
    Zepeda-Cervantes J; Vaca L
    Expert Rev Vaccines; 2018 Aug; 17(8):723-738. PubMed ID: 30074424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modern subunit vaccines: development, components, and research opportunities.
    Moyle PM; Toth I
    ChemMedChem; 2013 Mar; 8(3):360-76. PubMed ID: 23316023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
    Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
    Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposome-based vaccines.
    Schwendener RA; Ludewig B; Cerny A; Engler O
    Methods Mol Biol; 2010; 605():163-75. PubMed ID: 20072880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
    Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
    Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.
    Caproni E; Tritto E; Cortese M; Muzzi A; Mosca F; Monaci E; Baudner B; Seubert A; De Gregorio E
    J Immunol; 2012 Apr; 188(7):3088-98. PubMed ID: 22351935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
    Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
    Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
    Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
    Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses.
    Mahdavi M; Ebtekar M; Khorram Khorshid HR; Azadmanesh K; Hartoonian C; Hassan ZM
    Immunol Lett; 2011 Oct; 140(1-2):14-20. PubMed ID: 21679728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
    Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
    Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia.
    Kozako T; Fukada K; Hirata S; White Y; Harao M; Nishimura Y; Kino Y; Soeda S; Shimeno H; Lemonnier F; Sonoda S; Arima N
    Mol Immunol; 2009 Dec; 47(2-3):606-13. PubMed ID: 19889459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gp96 enhances the immunogenicity of subunit vaccine of porcine reproductive and respiratory syndrome virus.
    Chen C; Li J; Bi Y; Jia X; Meng S; Sun L; Liu W
    Virus Res; 2012 Aug; 167(2):162-72. PubMed ID: 22561908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.